http://www.tradingmarkets.com/.site/news/Stock%20News/920693/
<p>By Fain Hughes, Dec. 17, 2007 (TradingMarkets.com)- Synthetic Blood International, Inc. (SYBD) has finalized its Phase IIb Oxycyte(TM) clinical trial protocol for the treatment of traumatic brain injury (TBI), and plans to initiate three pre-clinical animal studies in sickle cell disease, spinal cord injury and stroke in the first half of 2008. Oxycyte is the Company’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. Previous animal studies have indicated that early intervention with Oxycyte helps to prevent the destruction of nerve cells in spinal cord injuries and provides oxygen to brain tissues in stroke…</p>